Norovirus P particle is an octahedral nanoparticle formed by 24 copies of the protrusion (P) domain of the norovirus capsid protein. This P particle is easily produced in E. coli, extremely stable, and highly immunogenic. There are three surface loops per P domain, making a total of 72 loops per particle, which are potential sites for foreign antigen presentation for immune-enhancement. To prove this concept, a small peptide (His-tag, 7 aa) and a large antigen (rotavirus VP8, 159 aa) were inserted into one of the loops. Neither insertion affects the P particle formation while both antigens were presented well on the P particle surface. The immune-enhancement effect of the P particle was demonstrated by significantly increased antibody titers induced by the P particle presented antigens compared to the free antigens. In addition, significantly higher neutralization antibody titers and protection against rotavirus shedding in mice immunized with the VP8 chimeric P particles compared to the free VP8 antigen were measured.
Introduction
Biomaterials and bioengineering are fast growing areas that have become critical parts of modern medicine. Because of their versatility and propensity to form arrays, viral structural proteins are ideal substrates to build presentation systems. Through genetic engineering, the self-assembled viral particles have been used as vaccine platforms for antigen presentation. Successful examples have been reported for several viruses, including flock house virus (FHV)-like particle (VLP) containing an antigen of Bacillus anthracis (20), hepatitis B virus (HBV) capsid-like particle (CLP) containing a surface antigen (OspA) of Borrelia burgdorferi (13, (22) (23) , and the cowpea mosaic virus (CPMV) presenting a number of different antigens (4-5, 10, 16-17, 25-26, 39) , although limitations have also been described in these presentation systems.
In our previous study of human noroviruses a unique subviral particle, the P particle, was discovered, which can be used for antigen presentation. Noroviruses cause epidemics of acute gastroenteritis in humans. The viruses are non-enveloped, containing an outer protein capsid consisting of a single major structural protein, the capsid protein (VP1). The capsid protein has two major domains, the shell (S) domain forming the interior shell and the protrusion (P) domain constituting the arch-like protruding structures of the virus (28). These two domains, linked by a flexible hinge (8 amino acids), can be structurally and functionally independent. Expression of the S domain alone forms a smaller, thin-layer particle with a smooth surface without binding function to histo-blood group antigen (HBGA) receptors (1, 32), whereas the P domain forms the P particle that binds to HBGAs (30, 35). Since the P particle is formed by the surface antigen of a norovirus and contains all required elements to interact with the viral receptors, it has been proposed as a vaccine candidate against norovirus (30, 35).
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The norovirus P particle is an octahedral nanoparticle with a diameter of ~20 nm and a molecular weight of ~840 kDa (Fig 1A) . It assembles spontaneously with 24 copies of the P monomers that organize into 12 P dimers (30, 35). This P particle is easily produced in E. coli and yeast, extremely stable, and highly immunogenic (30). The crystal structure of the norovirus P protein indicated three loops on the distal surface of each P domain (3) , corresponding to the outermost surface of the P particle (Fig 1) (30) .
Structure-based sequence alignment suggests that these loops may tolerate large sequence insertions (3), implying that they are potential sites for foreign antigen presentation. Since each P monomer has three surface loops, insertion of a foreign antigen into these loops will result in 24-72 copies of the antigen on the surface of a P particle, which could greatly enhance the antigenicity and immunogenicity of the antigens. Thus, the P particle may be an excellent nanocarrier for foreign antigen presentation.
In this study we evaluate the utility of the norovirus P particle as a carrier for vaccine development and antibody production. We first found that insertion of the His-tag as a small epitope to a loop of the P particle enhanced immunogenicity of the inserted His-tag in mice. Further study on rotavirus VP8 (159 amino acids) showed that the P particles can tolerate an insertion of large antigens. The VP8 is a trypsincleaved product of the surface spike protein VP4, which plays an important role in viral infectivity and neutralization of rotavirus and several neutralizing epitopes have been mapped on its surface (11-12, 14-15, 27) , indicating that the VP8 may be an excellent subunit vaccine candidate against rotaviruses. In addition to enhanced immunogenicity in mice, antibodies induced by the P particles-VP8 chimeras revealed strong neutralization and protection against rotavirus replication/infection in cell culture and in a murine rotavirus challenge model. The resulting antibody also blocked norovirus VLP binding to HBGA receptors, providing an opportunity to develop a dual vaccine against both noro-and rotaviruses.
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Our data proved the principle that the P particle is a multi-purpose platform for vaccine development and antibody productions.
Materials and methods
Expression constructs. The P particle expression vector (31, 34-35) of pGEX-4T-1 [Glutathione STransferase (GST) Gene fusion System, GE Healthcare life sciences] containing VA387 norovirus (GII.4) P domain-and a cystein-containing peptide-encoding sequences was used as the template for construction of various chimeric P particles. The cystein-containing peptide was to enhance and stabilize the P particle formation (35). For making the P particle-His-tag chimera, the His-tag-encoding sequence was inserted into loop 2 between N372 and D374 (Fig 1 and 2A ) through site-directed mutagenesis (see below). For the chimeric P particles containing human rotavirus VP8 antigens, a cloning cassette with enzyme sites of SpeI and ClaI/EcoRI was first introduced into loop 2 to replace the sequence from T369 to D374 (Fig 5A) by site-directed mutagenesis. The VP8 antigen cDNA sequences of a [P]8 stain (Wa, L65-L223, GenBank accession: VPXRWA) and a [P]4 strain (DS1, L65-l223, GenBank accession: VPXRDS) were cloned into the cassette. For cloning the cDNA sequence of murine rotavirus (EDIM) VP8 antigen (L65-L222, GenBank accession: AF039219) to the P particle, another cloning cassette with XbaI and Bgl II sites was inserted between N372 and N373. For making the P dimer-His-tag chimera, the His-tag was linked to the N-terminus of the P domain with the hinge (32, 35). Further purification of the resin-purified proteins was performed through gel filtration chromatography.
Gel filtration chromatography was carried out through an AKTA FPLC System (GE Healthcare life Sciences) as described previously (32, 35-36). Briefly, the affinity column-purified proteins were loaded on a size exclusion column Superdex 200 (GE Healthcare life Sciences) powered by an AKTA FPLC system (model 920, GE Healthcare life Sciences). The molecular weights of the eluted fractions were calibrated by Gel Filtration Calibration Kits (GE Healthcare life Sciences). Alternatively, the peaks of void volume, the chimeric P particle, and the P dimer can be determined by blue dextran 2000 (~2000 kDa, GE Healthcare life Sciences), the wild type P particle (830 kDa) and the wild type P dimer (69 kDa) of norovirus VA387 (GII.4), respectively (35). The fractions containing proteins of interest were further analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) and/or Western blot analysis.
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SDS PAGE and Western blot analysis. Recombinant proteins were analyzed by SDS PAGE using a 10% gel. The specific compositions of recombinant proteins were detected by a Western blot analysis as described elsewhere (32, 38) using hyperimmune sera against norovirus VLP (VA387, GII.4, 1:3000) or rotavirus VP8 antigen (Wa, 1:3000). Blotted membrane was blocked by 5% nonfat milk. Secondary antibody-HRP (horseradish peroxidase) conjugates (1:5,000, ICN Pharmaceuticals, Costa Mesa, CA) were used and the HRP was detected by ECL Eastern Blotting Detection Reagents (GE Healthcare life Sciences, Buckinghamshire, England). The ECL signals were captured by Hyperfilm ECL (GE Healthcare life Sciences, Buckinghamshire, England).
Site-directed mutagenesis was performed to insert His-tag and construct cloning cassettes in loop 2 of the norovirus P domain following the procedure of the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA) provided by the manufacturer as described previously (33). A primer pair: caccactgacacaaaccaccaccaccatcatcaccacgatcttcaaactggcc/ggccagtttgaagatcgtggtgatgatggtggtggtggtttgt gtcagtggtg was used for the insertion of a string of 7 histidines into loop 2 between N372 and D374 (Fig   1 and 2A) . In addition, a cloning cassette with three enzyme sites (Spe I and Cla I/EcoRI) in loop 2 of the norovirus P domain was constructed using primer pair gttcaatacaccactagtacaaacatcgatatccttcaaactggc/ gccagtttgaaggatatcgatgtttgtactagtggtgtattgaac to facilitate the insertion of the coding sequences of human rotavirus VP8 antigens. Another cloning cassette with XbaI and Bgl II sites was made using another primer pair tacaccactgacavaaactctagacacagatctaatgatcttcaaactgg/ccagtttgaagatcattagatctgtgtctagagtttgt gtcagtggtgta for the insertion of the coding sequence of murine rotavirus VP8 antigens.
Cryo-Electron microscopy (cryo-EM) techniques.
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Cryo-EM image collection. The procedure used for structure reconstruction of the wild type P particle described in our previous study (31) was adapted here. Briefly, aliquots (3-4 µl) of gel-filtration purified Cryo EM model evaluation and analysis. The crystal structure of rotavirus VP8 antigen (Wa, 2DWr, L65-L223) (2) was fitted into the extended protrusions of the 3D structure of the P particle-VP8 (Wa)
on October 28, 2017 by guest http://jvi.asm.org/ Downloaded from chimera using UCSF Chimera software (24). Simple rigid body motion was considered to find the best matching of the x-ray structure to the 3D structure of chimeric P particles.
Enzyme Immune Assay (EIA) was used to measure immune reactivity and antibody titers of mouse antisera after immunization with P particle-antigen chimeras. Different recombinant antigens were used for variable antisera: the His-tagged T. maritima α-L-Fucosidase for sera after immunization with the P particle-His-tag chimera, free VP8 for sera induced by the P particle-VP8 chimera, and GST for sera induced by the P particle-VP8 chimera with GST as internal control. Antigen was coated on a 96-well microtiter plate (Dynex Immulon; Dynatech, Franklin, Mass). After blocking with 5% nonfat milk, sera at indicated dilutions were incubated with the coated antigens. The bound antibody was detected by the secondary antibodies-HRP conjugate as described elsewhere (8, 38) . Antibody titers against antigens were defined as the endpoint dilution with a cut off signal intensity of 0.15. Sera from animals that were immunized with wild type P particle or PBS were used as negative controls.
HBGA binding and blocking assays. The saliva-based binding assays were carried out basically as described elsewhere (8) (9) . Briefly, boiled saliva samples with known HBGA phenotypes were diluted 1000 folds and coated on 96-well microtiter plates (Dynex Immulon; Dynatech, Franklin, MA). After blocking with 5% nonfat milk, VLPs or P particles of norovirus (VA387, GII.4) were added. The bound VLPs/P particles were detected using our home-made rabbit anti-VA387 VLP antiserum (1:3,300),
followed by the addition of HRP-conjugated goat anti-rabbit IgG (ICN, Pharmaceuticals, Costa Mesa, CA). The blocking effects of the mouse sera induced by the P particle-VP8 chimera on the norovirus VLP-saliva binding were measured by a pre-incubation of VLP with diluted serum for 30 min before the VLP was added to the wells with coated saliva. The blocking rates were calculated by comparing the on October 28, 2017 by guest http://jvi.asm.org/
ODs measured with and without blocking with the mouse sera from immunized animals. The blocking rates of the sera from free VP8 immunized animals were used as negative controls.
Immunizing mice for antibody responses. Female BALB/c mice at 6 weeks of age (Harlan-SpragueDawley, Indianapolis, IN) were immunized with purified chimeric P particles or free antigens at a dose 5-15 µg/mouse three to four times in a two-week interval. For comparison of the immune responses to the P particle-or P dimer-presented His-tag, 5 µg/mouse of recombinant P particle-His tag, P dimer-His tag, or wild type P particles were administered to mice (n =5). Same molar amount of free 7xhistidine
peptide was immunized to mice as control. The immunogens were given four times subcutaneously with the Freund's adjuvant. For comparison of the immune responses to the P particle-presented VP8 and free VP8, 5 µg/mouse of free VP8 and 15 µg/mouse of P particle-VP8 chimera, in which both immunogens are in the same molar amounts of VP8, were administered to mice either intranasally without an adjuvant or subcutaneously with Freund's adjuvant (n = 5-7) for three doses. In case of using GST as internal control, thrombin-digested GST-P-VP8 fusion protein that contained equal molar amount of GST and P particle-VP8 chimera were immunized to mice. Immunization of the chimeric P particle containing murine rotavirus VP8 to mice for protection is described below. Blood was collected by puncture of retroorbital capillary plexus before immunization and two weeks after the final immunization. Sera were processed from blood after overnight stay at 4 o C followed by centrifugation.
Rotavirus plaque assay was performed to determine neutralization of antisera from mice after immunization with chimeric P particle containing rotavirus VP8 antigen on rotavirus replication in cell culture. Tissue culture-adapted rotavirus Wa strain grown in MA104 monkey kidney cells were used in this assay. The MA104 cells were cultivated in 6-well plates and a rotavirus titer of ~50 plaque-forming on October 28, 2017 by guest http://jvi.asm.org/ Downloaded from units/well was used as the inoculum. For the assay, trypsin treated rotavirus was incubated with mouse sera at given dilutions for 60 min. The mixture was then added to the MA104 cells in the 6-well plate.
After 2 hours the plates were washed and then overlaid with media containing 5 µg/ml trypsin (Invitrogen, Carlsbad, CA) and 0.8% agarose. After a 4-day incubation at 37ºC, the numbers of plaques in each well were counted. The titer of neutralizing antibody in the sera was defined by the dilution of sera that showed ~20% reduction in plaque numbers in the wells treated with antisera comparing with that of untreated control wells.
Murine rotavirus challenge model. The rotavirus challenge model described in previous studies (6-7, 21) was followed to examine the protection efficacy of the P particle-VP8 vaccine. Rotavirus antibodyfree BALB/c mice (n =5-7) at 6 week of age (Harlan-Sprague-Dawley, Indianapolis, IN) were immunized intranasally three times with the chimeric P particle (15 µg/mouse) containing murine rotavirus (EDIM) VP8 antigen without an adjuvant. Free murine rotavirus VP8 antigen (5 µg/mouse) and the chimeric P particle (15 µg/mouse) containing human rotavirus (Wa) VP8 antigen were included for comparison. All these three immunogens contained the same molar amount of the VP8 antigen. In addition, the wild type P particle (vector control) and PBS were administered as negative controls. Two weeks after the last immunization, mice were challenged by oral gavage with murine rotavirus EDIM strain at a dose of 4 × 10 4 FFU (focus-forming units), which is equivalent to 10 5 50% shedding doses.
To measure rotavirus shedding in stools, two fecal pellets were collected from each mouse each day for 6 days following EDIM challenge and kept in 1 ml of Earle's balanced salt solution (EBSS). Samples were stored frozen until analyzed, at which time they were homogenized and centrifuged to remove debris. Quantities of rotavirus antigen in the fecal samples (µg/ml) were determined by ELISA as 
Results
Production of chimeric P particle containing a His-tag. Our study was initiated with an insertion of a small epitope, the poly-histidine (His) tag, into loop 2 of the P particle ( Fig. 1 and 2 ). Expression and purification of this chimeric P protein in E. coli using a GST-gene fusion system resulted in a high yield (>15 mg/liter culture) of the soluble protein with an expected size (~35 kDa) following a digestion of the protein to remove the GST tag (~27 kDa) by thrombin ( Fig 2C) . The formation of the chimeric P protein into P particles was shown by a gel-filtration chromatography followed by a SDS PAGE and a Western blot analysis, in which the chimeric P particle formed the major peak at ~840 kDa ( Fig 2D and E, Fig 3B, and data not shown). Exposure of the inserted His-tag on the chimeric P particle was shown by its specific binding to the Talon resin followed by an elution of the bound P particles with 250 mM imidazole ( Fig 3A, elution 1 and 2) , which resulted in a highly pure prep of the chimeric P particle. Thus, on October 28, 2017 by guest http://jvi.asm.org/ Downloaded from the P particles-His-tag chimera can also be purified from E coli using the affinity Talon resin (data not shown).
Immune enhancement of the His-tag by the P particle carrier. This was determined by examination of antibody responses to the His-tag in mice (n = 5) following immunization with the P particle-His tag chimera. A significantly higher antibody titer to His-tag was detected in the mice immunized with the P particle-His-tag chimera than that in mice immunized with the P dimer-presented His-tag or free 7xhistidine peptide (P < 0.05, Fig 4A and B) .
Development of a chimeric P particle containing the rotavirus VP8 antigen. We next examined the capacity of the P particle platform to accommodate a larger polypeptide by an insertion of the rotavirus (Wa) VP8 antigen that contains 159 amino acids. A cloning cassette with three enzyme sites (Spe I and Cla I/EcoRI) in loop 2 of the P particle was constructed (Fig 5A) to facilitate the VP8 insertion.
Expression of the construct in E. coli resulted in a high yield (> 20 mg/liter culture) of the GST-P-VP8 fusion protein (~78 kDa, Fig 5B, left panel) . Released P-VP8 chimera (~52 kDa) was obtained by thrombin digestion of the GST fusion protein either in solution or on the purification beads (Fig 5B, middle and right panels, respectively). High rate (> 95%) of P particle formation of the P-VP8 chimeric protein was demonstrated by gel-filtration chromatography ( Fig 5C) . Western blot analysis showed that the P-VP8 chimeric protein reacted with antibodies against both norovirus VLP (VA387) and rotavirus (Wa) VP8 (Fig 5D) .
Cryo-EM and 3-dimentional image reconstruction showed that the P particle-VP8 chimera remains an octahedral symmetry like the wild type P particle (31) but the chimeric P particle is notably larger ( 6A and B). The extended protrusion is likely the inserted VP8 that can be recognized by a nick as the potential boundary from the P dimer. Fitting of the crystal structure of rotavirus VP8 antigen of the same Wa strain (2) in the density map of the extended protrusions of the chimera confirmed that the extended protrusion is indeed the VP8 (Fig 6C to E) .
The P particle enhanced immune responses to VP8. We then studied the immune responses to the P particle presented VP8 antigen in mice. Following immunization with equal molar amounts of the P particle-VP8 chimera, free VP8, and GST, the resulting mouse sera were examined by EIA using free VP8 or GST as antigen (see Materials and Methods). The antibody titer against VP8 after immunization with the P particle-VP8 chimera was significantly higher than that induced by the free VP8 following an intranasal immunization without an adjuvant (P < 0.005). Comparable results were observed for two chimeric P particles containing a VP8 antigen of rotaviruses Wa ([P]8) and DS-1 ([P]4), respectively, comparing to their free VP8 counterparts (Fig 7A and B) . Only marginal antibody titer against free GST was detected in these animals, further confirming the specific immune enhancement to the P particle presented VP8s. The immune responses of mice following a subcutaneous immunization of above antigens with the Freund's adjuvant were also studied and less difference of antibody titers to VP8
between the free-and P particle presented-VP8 were observed (Fig 7C) .
The P particle-VP8 chimera induced neutralizing antibodies against rotaviruses. The hyperimmune antisera induced by the P particle-VP8 (Wa, [P]8) chimera through an intranasal immunization (Fig 7A) strongly reduced the homologous rotavirus (Wa) replication in cell culture. This effect was significantly stronger than that by immunization with the free VP8 (P < 0.0002) (Fig 8A) . A low level of crossinhibition of the sera after immunization with P particle-VP8 (DS-1, [P]4) chimera to Wa was also on October 28, 2017 by guest http://jvi.asm.org/ Downloaded from observed (P < 0.05, Fig 8B) . In contrast, sera from animals immunized with the free VP8 of DS-1 did not show such cross inhibition. In addition, the neutralization titers using sera from subcutaneously immunized animals with the Freund's adjuvant were also measured. To our surprise, among 4 pairs mouse sera with similar immune reactivities to free VP8 antigen in EIAs (Fig 8C) , all sera from animals immunized with the P particle-VP8 (Wa) chimera showed significantly higher neutralization titers than that of sera from mice immunized with free VP8 of the homologous Wa strain (P < 0.005, Fig 8D) .
These data indicated that the VP8 on the chimeric P particle might be better presented and maintained a proper conformation that is required for a neutralization epitope.
Vaccination with the P particle-VP8 chimera reduced viral shedding after challenge with a murine rotavirus. We next examined whether a P partilce-VP8 chimeric vaccine could provide protection in vivo using a murine rotavirus model (EDIM strain) (6-7, 21). To this end, a chimeric P particle containing the EDIM VP8 antigen was constructed and administered to mice (see Materials and Methods). After confirmation of antibody responses to murine rotavirus VP8 (Fig 9A) , the animals were challenged with murine rotavirus and their virus shedding was measured (Table 1 , Fig 9B) . Mice vaccinated with the P particle-VP8 (EDIM) chimera shed a significantly lower quantity of viral antigen than mice immunized with the wild type P particle (vector control, P < 0.05) and mice vaccinated with P particle-VP8 (Wa) chimera (P < 0.05). The average reduction of viral shedding was 89% in the six-day period with a particularly high reduction (99.2%) on day 1 after viral challenge. Mice immunized with free murine VP8 had an average reduction of 77%, which is lower than that of mice immunized with the P particle-VP8 (EDIM) chimera (P > 0.05). Immunization with the chimeric P particle vaccine containing a human rotavirus (Wa) VP8 had a low to modest effect (23%) on viral shedding (Table 1 on October 28, 2017 by guest http://jvi.asm.org/
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and Fig 9B) , suggesting some cross-protection against EDIM. This heterologous protection became more apparent on day 6 after the viral challenge (63%, P < 0.05, Table 1 ).
Immunization with the P Particle-VP8 chimera induced antibody that blocked norovirus binding to HBGA receptor. The role of the P particle backbone in immune responses in mice was also examined following immunization with the P particle-VP8 (Wa) chimera. As expected, the mouse sera after immunization with chimeric vaccines reacted strongly with norovirus VLPs and P particles as determined by EIAs (Fig 10A, data not shown) . More importantly, these sera blocked norovirus VLP binding to HBGA receptors (Fig 10B, data not shown) . As a negative control, sera from animals immunized with the free VP8 (Wa) did not show such blockade. This result indicates that the P particle-VP8 chimera could be a dual vaccine against both rotavirus and noroviruses.
Discussion
Our previous studies showed that the norovirus P particle is easily produced, extremely stable and highly immunogenic and can be used as a subunit vaccine against noroviruses (30, 35). In this study we further demonstrated that the P particle can also be used as a novel vaccine platform for immune enhancement of a foreign antigen. We have shown that: 1) the surface loops of the P particle are excellent sites for foreign antigen insertion without affecting the formation and production of the P particle, 2) the P particle tolerates a foreign antigen in a size up to at least to 159 amino acids, 3) the enhanced immune responses to inserted antigens have been demonstrated by both in vitro neutralization and in vivo protection experiments. The P particle-VP8 chimera served as a promising dual vaccine against both rotavirus and norovirus. Thus, the simple procedure to generate chimeric particles and the multiple surface loops with potential multi-polyvalent foreign insertion make the P particle an attractive vaccine on October 28, 2017 by guest http://jvi.asm.org/ Downloaded from platform for antigen presentation for infectious diseases or other medical conditions that would benefit from an efficient vaccine.
A primary goal of this study was to examine whether the P particle can enhance immunogenicity of a small polypeptide antigen that is generally low immunogenic. We first studied this issue using the Histag as a model and obtained excellent results. Two major factors may be responsible for the observed immune enhancement, multi-copy number and surface exposure of the inserted antigens. The P particle is composed of 24 copies of P monomers, which may explain its enhanced immune responses comparing with a free His-tag peptide and the His-tag fused to a P dimer (Fig 4A) .. Thus, the P particle may act as an adjuvant by its large size (830 kDa) and proper presentation of a foreign antigen that otherwise has low immunogenicity. The increased multi-copy of an antigen per particle is another feature that may explain the increased immune responses.
In addition to the His-tag peptide, we have successfully inserted a number of other small peptides onto the P particles, including the T cell epitope of murine cytomegalovirus (9 aa), the Epi8 epitope of Pseudomonas (14 aa), the T cell epitope of murine rotavirus VP6 (14aa), and the M2 extracellular epitope of influenza virus (M2e, 23 aa) (Tan, M and Jiang, X, unpublished). Significantly increased immune response and protection of the M2e antigen through the P particle platform has also been demonstrated in a mouse model (Xia, M, Tan, M and Jiang, X, unpublished). These data suggested that the P particle may be readily useful for immune enhancement for a wide variety of small polypeptide antigens. The successful insertion of different rotavirus VP8s (159 aa) and the green fluorescence protein (GFP, 238 aa) into P particles (this reported; Tan, M and Jiang, X, unpublished) has greatly extended the application of the P particle platform for a wider range of larger foreign antigens. The on October 28, 2017 by guest http://jvi.asm.org/ Downloaded from rotavirus VP8 is a spike protein on the viral capsid and is believed to be important for rotavirus infectivity. It is also one of two rotavirus antigens that induce neutralizing antibodies. A number of neutralizing epitopes have been identified on the VP8 protein (11-12, 14-15, 27 ). The success of the P particle-VP8 chimera to induce a neutralizing antibody response and provide protection against rotavirus shedding in mice suggested that these epitopes have been preserved on the P particle carrier.
Future study to develop the P particle-VP8 chimera into a useful vaccine against rotaviruses is warranted.
While the two recently introduced rotavirus vaccines are highly effective, new generation vaccines may be needed for potentially new emerging viruses. Non-infectious subunit vaccines do not have a risk of reversion to virulent strains. The development of a VLP vaccine for rotaviruses has been proposed for years. However, rotavirus VLP vaccine faces the challenge of low efficiency expression and high cost of manufacturing because of the requirement for co-transfection of several capsid genes to the baculovirus host. In contrast, generation of the P particle-VP8 chimera requires only a routine E. coli-based cloning and expression procedure, which is highly efficient and low in cost. In addition, cross-neutralization epitopes have been described on VP8. We have shown in this paper that immunization of mice with a chimeric P particle containing VP8 from a P [4] virus had cross neutralization against a P[8] rotavirus (Fig 8B) . A cocktail vaccine containing minimal number of P types may also be cost effective.
The ability of antibodies induced by the P particle-VP8 chimera to block the binding of norovirus VLPs to HBGAs is unexpected. As shown in Fig 6 , the distal surface of the P dimers, including the HBGA binding interfaces (3, 37) of the P particle is most likely to be covered by the inserted VP8s. This leads to the loss of the binding capability of the chimera to HBGA receptors (data not shown). One possibility for the continued blocking ability seen, is that the epitopes of the HBGA binding interfaces of the P on October 28, 2017 by guest http://jvi.asm.org/ Downloaded from particle-VP8 chimera are still accessible for host immune response even thought they are covered by the inserted VP8 antigens. Alternatively, the observed carbohydrate blockage may be due to an antibody binding in the vicinity of the carbohydrate binding site. No matter which mechanism is involved, the ability of the chimera-induced antibody to block norovirus VLP binding to HBGAs adds an additional value to the P particle platform. The concept of a dual vaccine of the P particle-VP8 chimeric against both norovirus and rotavirus may be particularly valuable for specific populations at risk for both infections.
Although only data on loop 2 of the P particle (Fig 1) was reported in this manuscript, success of various antigen insertions in the other two loops has been demonstrated (Wang, LY, Tan, M and Jiang, X, unpublished). The availability of three surface loops per P monomer provides opportunities for versatile vaccine designs. For example, to increase immune responses, the same epitope or antigen can be inserted in all three loops to reach 72 copies of the antigens per particle. Even higher copy number can also be generated by insertion of tandem-repeats of individual antigens. Alternatively, different antigens can be inserted into each of the three loops, resulting in a multi-valent vaccine against different pathogens. Additional vaccine templates may also be generated by insertion of functional tags for different purposes. For example, insertion of a His-tag would further simplify the purification procedure.
Special ligands or signal molecules may also be used to stimulate immune responses by targeting the vaccine to special organs, tissues or cells of the host. A potential drawback of using a norovirus particle vaccine platform could be the pre-existing antibodies to noroviruses in human. Thus, further studies are required to clarify this issue.
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A further application of the P particle platform is for production of antibodies against small peptides for research and diagnostic uses. A variety of disease biomarkers (mainly peptide epitopes) has been identified and antibodies against these biomarkers are important for diagnostic purpose. Small peptides can be easily inserted into a loop of the P particle by a simple procedure of DNA cloning. We have developed convenient P particle vectors containing cloning cassettes that would further facilitate the process. Following expression of the recombinant chimeric P particle in bacteria, high titer antibodies specific to the inserted peptide antigens can be made by immunization of laboratory animals with the chimeric P particle according to the established procedure in this study. Antibody production in this way will avoid the costly steps of peptide synthesis and conjugation of the peptide to a macromolecule such as keyhole limpet hemocyanin (KLH) for immune enhancement. Since the norovirus P domain has a unique sequence that shares no homology with any other proteins, cross reactivity with other proteins should not be a concern. Thus, the P particle vaccine platform can be used as a convenient tool for antibody production in many areas of biomedical research.
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The research described in this article was supported by the National Institute of Health, the National the elution curve of a gel filtration chromatography of the thrombin-released P-domain-His tag protein through the size exclusion column Superdex 200. Three major peaks representing void, P particle-Histag and P dimer-His-tag were indicated, respectively. The sizes of these three peaks were calibrated with on October 28, 2017 by guest http://jvi.asm.org/ Downloaded from blue dextran 2000 (~2000 kDa, void), wild type P particle (~830 kDa), and wild type P dimer (~70 kDa), respectively. (E) the fractions of the gel filtration chromatography (D) were analyzed by SDS PAGE and the fractions representing the three peaks were indicated. Figure 3 . Exposure of the His-tag on the P particle. (A) the GST-P domain-His tag fusion protein was digested by thrombin, resulting in a mixture of the P particle-His-tag chimera (PP-His-tag), GST and other co-purified proteins. These mixed proteins (before loaded) were loaded to the Talon resin and the flow through contained all proteins except the P particle-His-tag chimera. After wash (last wash) the P particle-His-tag chimera was eluted (elution 1 and 2) by 250 mM imidazole. Immune responses of mice to P particle presented VP8s. Equal molar amount of the P particle-VP8 chimera and free VP8 were used to immunize mice, either intranasally without an adjuvant (A and B, n = 5-7), or subcutaneously with the Freund's adjuvant (C, n = 6-7). Free VP8 and GST were used as antigens for antibody titer determination in EIAs. (A and B) antibody titers of mouse sera against VP8
and GST after immunization with free VP8 antigen (free VP8) and the chimeric P particles (PP-VP8)
containing VP8s of Wa (A) and DS1 (B), respectively. (C), antibody titers against VP8 after immunization with free VP8 antigen (free VP8) and the chimeric P particle (PP-VP8) containing VP8 of Wa strain. In all experiments equal molar amount of GST in the immunogens served as internal control. ** P < 0.01. Figure 8 . Neutralization to rotavirus by mouse sera after immunization with P particle-VP8 chimeras. (A) mouse sera after intranasal immunization with P particle-VP8 (Wa, [P]8) chimera without an adjuvant shows strong neutralization to the same Wa strain (PP-VP8 sera, blue), while sera after immunization with free VP8 show significantly lower neutralization (VP8 sera, black). Sera from mice receiving no antigen served as negative controls (control sera, purple). (B) mouse sera after immunization with the P particle-VP8 (DS1, [P]4) chimera shows weak cross neutralization to Wa (PP-VP8 sera, blue), whereas sera after immunization with free VP8 of DS1 (VP8 sera) and the negative control sera did not show this cross neutralization (black and purple). (C), immune reactivity against VP8 of sera from mice immunized with free Wa VP8 (VP8 sera, black) and P particle-VP8 (Wa) chimera (PP-VP8 sera, blue) the sera from (C) after immunization with P particle-VP8 chimera showed significantly higher neutralization titers to rotavirus (Wa) (PP-VP8 sera, blue) than that of sera induced by immunization with free VP8 (VP8 sera, black). Control sera from mice receiving no antigen served as a negative control (control sera, purple). The star symbols indicate the P values between the neutralization of the sera after immunization with the two forms of VP8: * P<0.05; **, P<0.01, and ***, P<0.001. Figure 9 . Protection after immunization of mice with P particle-VP8 chimeric vaccine against a mouse rotavirus infection. (A) Antibody responses of mice to free murine rotavirus VP8 after vaccination with free (free mVP8) and P particle presented (PP-mVP8) murine rotavirus VP8. The wild type P particle were vaccinated with the wild type norovirus P particle (vector control, n = 7). PP-hVP8, mice were vaccinated with P particle-VP8 (Wa) chimera (n = 5). Free mVP8, mice were vaccinated with free murine VP8 (EDIM) antigen (n = 5). PP-mVP8, mice were vaccinated with P particle-VP8 (EDIM) chimera (n = 5). Data calculation and statistic analysis are shown in Table 1 . Fig 10. Mouse sera after immunization with P particle-VP8 chimeras block binding of norovirus VLP to HBGA receptor. (A) mouse sera after immunization with the P particle-VP8 (Wa) chimeras reacted strongly to norovirus P particle (PP-VP8), while sera after immunization with the free VP8 did not show this reactivity (free VP8). (B) mouse sera from (A) blocked binding of norovirus VLP to HBGA receptor (type A saliva, PP-VP8 sera, blue), while sera after immunization with free VP8 did not show this blockade (VP8 sera, black). Mice were immunized intranasally as described in Materials and Methods. Two weeks after the last immunization mice were challenged with 10 5 Shedding Dose 50 of murine EDIM. Stools were collected from each mouse for 6 days after challenge and analyzed for the quantity of rotavirus antigen. 2 Mean shedding per mouse per day in each group. 3 Protection is the percent reduction in shedding compared to the control group, either by day or over the 6 days. 4 P values were calculated by comparing to the control group vaccinated with the wild type P particle. A star symbol indicates statistically significant (P<0.05), while a double star symbol indicates statistically very significant (P<0.01). 6  1  7  1  8  1  9  2  0  2  1  2  2  2  3  2  4  2  5  2  6  2  7  2  8  2  9  3  0  3  1  3  2  3  3 
